Współczesne wykorzystanie tikagreloru w ośrodkach medycznych w Polsce jako odzwierciedlenie przestrzegania wytycznych dotyczących terapii przeciwpłytkowej

Abstract

Introduction. Ticagrelor is the newest P2Y 12 inhibitor recommended as the first treatment option for acute myocardial infarction both with and without ST-segment elevation. Recent studies have revealed unsatisfactory use of novel P2Y 12 inhibitors. The aim of our study was to assess the contemporary use of ticagrelor in major medical centres located in Kuyavian-Pomeranian, Pomeranian, and Warmian-Masurian voivodships. Materials and methods. Retrospective analysis of hospital records regarding the number of ticagrelor tablets purchased monthly was performed covering a three-year period from January 2015 to December 2017. Data from 15 major medical centres was analysed. Results. A total of 78,871 tablets of ticagrelor were purchased over the study period, with a monthly median of 2,013.5 and an interquartile range (IQR) of 1,255–2,996. The amount of ticagrelor increased monthly by 7.9%. The lowest monthly value (294, 0.37%) was recorded in the first month, while the highest (4,550, 5.77%) was in October 2017. The median of tablets purchased in 2017 (3,934, IQR 3,010–4,270) was over four times greater than in 2015 (980, IQR 728–1,288, p Conclusions. The use of ticagrelor has been significantly increasing in recent years, which reflects the implementation of current guidelines by medical centres. Substantial heterogeneity regarding the use of ticagrelor is observed within particular centres.